HK Stock Market Move | GENSCRIPT BIO (01548) rises over 5% to hit a new high again; recently reached a partnership with Eli Lilly; AIDD drives strong growth in life sciences.

GENSCRIPT BIO (01548) rose over 5% in morning trading, reaching a high of HK$48.38, hitting a new all-time high again. As of press time, it was up 5.74% at HK$48.26, with a turnover of HK$95.6246 million. On the news front, GenScript recently announced a partnership with Eli Lilly's AIDD collaboration platform Lilly TuneLab. Under the agreement, the company will provide wet lab services to TuneLab participating companies, helping them rapidly generate experimental data, convert AI predictions into biological validation data, and accelerate candidate drug evaluation. JPMorgan stated that this move is a strategic entry point into an ecosystem of over 100 biotech clients, closing the loop between dry and wet lab experiments. China Securities Co.,Ltd. noted that GenScript's AIDD-related revenue in the first half of the year approached US$40 million, and it is expected to maintain rapid growth in the coming years. The company recently completed a Hong Kong stock placement, with the proceeds expected to be mainly used for AIDD capacity building. As AI drug discovery gradually moves from computational science toward deep integration with experimental science, the company is expected to continue benefiting.